The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic…
In Conversation
Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It…
Your professional career went back and forth between creating your own business and running a smaller and very dynamic structure and managing over a thousand of…
You were recently appointed at the head of Eli Lilly South African operations. What is the specific mission you have been given? Eli Lilly South Africa…
Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have…
Mr Fadıllıoğlu, after a previous position at Abbott, you were recently appointed head of GSK Turkey. How different is GSK as an organization? What new therapeutic…
Mr Acar, could you present to our readers the Institution’s historical development and its role today in the Turkish pharmaceutical and healthcare sector? Before Social Security…
Mrs Aygun, could you please introduce yourself to our readers and give us an overview of CORENA? I have an educational background in chemistry and a…
You are among the youngest GM’s of the top 200 companies in Turkey. What factors would you attribute to the rapid advancement of your career? I…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to…
Mr Yusuf, Pharmaceutical Executive’s readers are keen to discover, through our reports, prominent industry personalities, and they like to hear their stories. Having been instrumental in…
With forty years of experience behind your belt, you founded JOSWE in 2000. What were the opportunities in the market that you saw to establish the…
